🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

AT101, a new #CART with a distinct binding mechanism is showing promising early responses, according to data published today in @SN_Oncology. Poster session at #ASH23 at 5:30pm PT. Marco Ruella Penn Medicine - Abramson Cancer Center ASH spr.ly/6011Rz4mU

Yunlin Zhang is ready to present her poster on a first-in-human CART19 targeting a non-FMC63 CD19 epitope with low avidity. Ruella Lab #ASH23 published today! Ruchi Patel molecular-cancer.biomedcentral.com/articles/10.11…

Puneeth Guruprasad from the Ruella Lab showing our newest data on the role of modulation of BTLA in CART immunotherapy #ASH23 Penn Medicine

Mat Angelos from our Ruella Lab presenting for the for the first time a novem CD2 deleted CART2 for T-ALL: High preclinical efficacy against primary leukemias #ASH23 Penn Medicine

Tazemetostat enhances #CART immunotherapy for #NHL. Patrizia Porazzi from our Ruella Lab presenting her newest results at #ASH23 Penn Medicine ASH Clinical News Saad kenderian

#NHL #HCL cell targeting with #CART but no B-cell aplasia? It might be possible with VH4-34 CART as presented at #ASH23 by Ivan Cohen of the Ruella Lab from Penn Medicine Saad kenderian